DDInter812 DDInter1676
Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. Gemfibrozil was granted FDA approval on 21 December 1981.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Gemfibrozil {u} (Compound) resembles {v} (Compound) Bupranolol
Gemfibrozil {u} (Compound) treats {v} (Disease) coronary artery disease
Gemfibrozil {u} (Compound) binds {v} (Gene) CYP3A4
Gemfibrozil {u} (Compound) upregulates {v} (Gene) SRC
Gemfibrozil {u} (Compound) is included by {v} (Pharmacologic Class) PPAR alpha
Gemfibrozil {u} (Compound) downregulates {v} (Gene) GOLT1B
Gemfibrozil {u} (Compound) causes {v} (Side Effect) Urticaria
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Gemfibrozil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Gemfibrozil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Gemfibrozil (Compound) resembles Bupranolol (Compound)
Gemfibrozil (Compound) treats coronary artery disease (Disease)
Gemfibrozil (Compound) binds CYP3A4 (Gene)
Gemfibrozil (Compound) upregulates SRC (Gene)
Gemfibrozil (Compound) is included by PPAR alpha (Pharmacologic Class)
Gemfibrozil (Compound) downregulates GOLT1B (Gene)
Gemfibrozil (Compound) causes Urticaria (Side Effect)
Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Gemfibrozil may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Gemfibrozil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide